Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 391-399

  Chi, Dennis S ^a   Schwartz, Peter E ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; OVARY CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 56449108337     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.07.058     Document Type: Note

References (58)

1. Eisenkop S.M., Spirtos N.M., Friedman R.L., et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advance ovarian cancer: a prospective study. Gynecol. Oncol. 90 2 (2003) 390-396
2. Alletti G.D., Dowdy S.C., Gostout B.S., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107 1 (2006) 77-85
3. Eisenhauer E., Abu-Rustum N., Sonoda Y., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103 3 (2006) 1083-1090
4. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer. Inst. Mongr. 421 (1975) 101-104
5. Griffiths C.T., and Fuller Jr. H.F. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg. Clin. North. Am. 58 (1978) 131-142
6. Hoskins W.J., Bundy B.N., Thigpen J.T., et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47 (1992) 159-166
7. Crawford S.C., Vasey P.A., Paul J., et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from and international comparison within the SCOTROC-1 trial. J. Clin. Oncol. 23 (2005) 8802-8811
8. Crawford S.C., Paul J., Kaye S.B., et al. Aggressive surgery and ovarian cancer. J. Clin. Oncol. 24 (2006) 2396-2397
9. Crawford S.C., Paul J., Kaye S.B., et al. Importance of surgical aggressiveness in advanced ovarian cancer. J. Clin. Oncol. 24 (2006) 2398-2399
10. Hoskins W.J., Bundy B.N., Thigpen J.T., et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47 2 (1992) 159-166
11. Winter W.E., Maxwell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 25 24 (2007) 3621-3627
12. Chi D.S., and Barakat R.R. Aggressive surgery and ovarian cancer. Clin Oncol 24 15 (2006) 2395
13. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
14. Aletti G.D., Dowdy S.C., Podratz K.C., et al. Analysis of factors impacting operability in Stage IV ovarian cancer. Rationale use of a triage system. Gynecol. Oncol. 105 (2007) 84-89
15. Salani R., Axtell A., Gerard M., et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 108 (2008) 271-275
16. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma?. Gynecol. Oncol. 103 (2006) 559-564
17. Winters III W.E., Maxell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25 (2007) 3621-3627
18. Winters III W.E., Maxell G.L., Tian C., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 26 (2008) 83-89
19. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., et al. The effect of maximum surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol. Oncol. 108 (2008) 276-281
20. Nelson B.E., Rosenfield A.T., and Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol. 11 1 (1993) 166-172
21. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of cytoreduction in Stage IV epithelial ovarian cancer. Gynecol. Oncol. 72 (1999) 278-287
22. Chi D.S., Franklin C.C., Levine D.A., et al. Improved optimal cytoreductive rates for stages IIIC IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 3 (2004) 650-654
23. Axtell A.E., Lee M.H., Bristow R.E., et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25 4 (2007) 384-389
24. Salani R., Axtell A., Gerardi M., Holschneider C., and Bristow R.E. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 108 2 (2008 Feb) 271-275
25. Berchuck A., Iversen E.S., Lancaster J.M., Dressman H.K., West M., Nevins J.R., and Marks J.R. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am. J. Obstet. Gynecol. 190 4 (2004 Apr) 910-925
26. Angioli R., Palaia I., Zullo M.A., et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol. Oncol. 100 3 (2006) 455-461
27. Nelson B.E., Rosenfield A.T., and Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol. 11 (1993) 166-172
28. Qayyum A., Coakley F.V., Westphalen A.C., et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol. Oncol. 96 (2005) 301-306
29. Byrom J., Widjaja E., Redman C.W.E., et al. Can preoperative computed tomography predict respectability of ovarian carcinoma at primary laparotomy?. Br. J. Obstet. Gynaecol. 109 (2002) 369-375
30. Bristow R.E., Duska L., Lambrou N., et al. A model for predicting surgical outcomes in patients with advanced ovarian carcinoma using computed tomography. Cancer 89 (2000) 1532-1540
31. Dowdy S., Mullany S., Brandt K., et al. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101 (2004) 346-352
32. Axtell A.E., Lee M.H., Bristow R.E., et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25 (2007) 384-389
33. Deffieux C., Castaigne D., and Pomel C. Role of laparoscopy to evaluated candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int. J. Gynecol. Cancer. 16 (2006) 35-40
34. Fagotti A., Ferrandina G., Fanfani F., et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann. Surg. Oncol. 13 (2006) 1156-1161
35. Berchuck A., Iversen E.S., Lancaster J.M., et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am. J. Obstet. Gynecol. 190 (2004) 910-925
36. Hue J.Y., Kelly M.G., Yu H., et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol. Oncol. 105 (2007) 211-217
37. Morrison J., Swanton A., Collins S., and Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane. Database. Syst. Rev. 17 4 (2007 Oct) CD005243
38. Bristow R.E., Tomacruz R.S., Armstrong D.K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 5 (2002) 1248-1259
39. Rose P.G. The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am. J. Obstet. Gynecol. 166 (1992) 843-846
40. Kuhn W., Florack G., Roder J., et al. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and IV. Int. J. Gyn. Cancer. 8 (1998) 56-63
41. Chi D.S., Eisenhauer E.L., Sonoda Y., Abu-Rustum N.R., Gemignani M., Levine D.A., Huh J., Kardos S., Hensley M., Sabbatini P., Aghajanian C., Spriggs D., et al. Improved overall survival for patients with advanced ovarian, tubal, and primary peritoneal carcinoma as a result of a change in surgical approach: a follow-up study (abstr). J. Clin. Oncol. 25 18S (2007) 281s
42. Hou J.Y., Kelly M.G., Yu H., et al. Neoadjuvant chemotherapy lessons surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol. Oncol. 105 1 (2007) 211-217
43. Bristow R.E., and Chi D.S. Platinum based neoadjuvant chemotherapy and interval cytoreduction for advance ovarian cancer: a meta-analysis. Gynecol. Oncol. 103 3 (2006) 1070-1076
44. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351 (2004) 2489-2497
45. van der Burg M.E.L., van Lent M., Buyse M., et al. The effect of debulking after induction chemotherapy on the prognosis of advanced epithelial ovarian cancer. N. Engl. J. Med. 332 (1995) 629-634
46. Onda T., Matsumoto K., Shibata T., et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for Stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group study. JCO 0602. Jpn. J. Clin. Oncol. 38 (2008) 74-77
47. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol. 103 (2006) 1070-1076
48. Bristow R.E., Eisenhauer E.L., Santillan A., et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol. Oncol. 104 (2007) 480-490
49. Aletti G.O., Santillan A., Eisenhauer E.L., et al. A new frontier for quality of care in gynecologic oncology surgery: multi-Institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol. Oncol. 107 (2007) 99-106
50. Eisenkop S.M., Friedman R.I., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
51. Eisenkop S.M., and Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival?. Gynecol. Oncol. 82 (2001) 435-441
52. Eisenkop S.M., Spirtos N.M., Friedman R.L., et al. Relative influence of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer. a prospective study. Gynecol. Oncol. 90 (2003) 390-396
53. Scholz H.S., Tasdemir H., Hunlich T., et al. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol. Oncol. 106 (2007) 591-595
54. Juretzka M.M., Abu-Rustum N.R., Sonada Y., et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol. Oncol. 104 3 (2007) 670-674
55. Eitan R., Levine D.A., Abu-Rustum N., et al. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 103 7 (2005) 1397-1401
56. Juretzka M.M., Abu-Rustum N., Sonoda Y., et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol. Oncol. 104 (2007) 670-674
57. Rafii A., Deval B., Geay J.F., et al. Treatment of FIGO stage IV ovarian carcinoma: Results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. Int. J. Gynecol. Cancer. 17 (2007) 777-783
58. Vergote I., deWever I., Tjalma W., et al. Neoadjuvant chemotherapy or primary surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71 (1998) 431-436